Teva (NYSE: TEVA) holder plans $6.23M Rule 144 ordinary share sale

Rhea-AI Filing Summary

Teva Pharmaceutical Industries insider plans Rule 144 share sale. A holder has filed to sell 216,892 ordinary shares of Teva through Citigroup Global Markets on the NYSE, with an aggregate market value of $6,230,750.00 as of the notice. Teva had 1,147,282,512 ordinary shares outstanding, providing context for the size of the planned sale.

The securities to be sold were acquired in two ways: 98,168 shares were received on 03/01/2021 in a rollover transaction from Teva Pharmaceutical Industries Limited, and 118,724 shares were obtained via a cashless exercise of stock options, with cash payment dated 12/09/2025. The seller represents that they are not aware of any undisclosed material adverse information about Teva’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS INC 390 GREENWICH STREET NEW YORK NY 10013	216892	6230750.00	1147282512	12/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/01/2021	SHARES FROM ROLLOVER	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			98168	12/09/2025	COMPENSATION
Ordinary Shares	12/09/2025	CASHLESS EXERCISE STOCK OPTIONS	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			118724	12/09/2025	CASH

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for TEVA disclose?

The filing discloses that an insider or affiliated holder of Teva Pharmaceutical Industries intends to sell 216,892 ordinary shares under Rule 144 on the NYSE through Citigroup Global Markets, with an aggregate market value of $6,230,750.00.

How large is the planned TEVA share sale compared with shares outstanding?

The notice lists 216,892 ordinary shares to be sold, while 1,147,282,512 shares of Teva were outstanding, giving a sense of the relative size of the potential sale.

How were the TEVA shares in this Form 144 acquired?

The securities were acquired in two ways: 98,168 shares were received on 03/01/2021 as shares from rollover from Teva Pharmaceutical Industries Limited, and 118,724 shares were obtained via cashless exercise of stock options with a cash payment dated 12/09/2025.

Which broker will handle the TEVA shares sale under this Form 144?

The notice states that the ordinary shares are to be sold through Citigroup Global Markets Inc., located at 390 Greenwich Street, New York, NY 10013, on the NYSE.

What representation does the seller make in the TEVA Form 144 notice?

The person for whose account the securities are to be sold represents that they do not know any material adverse information about Teva’s current or prospective operations that has not been publicly disclosed.

Does the Form 144 mention recent TEVA share sales by this person?

The section requesting information on securities sold during the past 3 months is included, but no specific sales data are provided in the excerpt.